Immunodeficiency 43 (IMD43) Cell Models for Research

Immunodeficiency 43 (IMD43) is a rare primary immunodeficiency disorder characterized by recurrent infections, particularly affecting the respiratory tract, and autoimmunity. The exact prevalence is unknown, but it is considered extremely rare, with fewer than 1 in 1,000,000 individuals affected. The condition is caused by mutations in the ZNF341 gene, leading to defective STAT3 signaling and impaired Th17 cell differentiation. Clinically, patients present with recurrent pneumonia, bronchiectasis, and chronic mucocutaneous candidiasis. The disease has a significant impact on quality of life and can be life-threatening if not managed with immunoglobulin replacement and prophylactic antibiotics. Early diagnosis and treatment are critical for improving outcomes.

IMD43 serves as an excellent model for studying the molecular mechanisms of STAT3 signaling and Th17 cell differentiation. The disease is monogenic, making it amenable to gene editing studies. Public datasets, such as those from the International Union of Immunological Societies (IUIS) and ClinVar, provide comprehensive mutation data. Open questions include the precise role of ZNF341 in regulating STAT3 expression and the potential for targeted therapies. Gene-edited cell models, such as ZNF341 knockout lines, are invaluable for dissecting these pathways and testing novel therapeutic approaches.

Although IMD43 is not a cancer, the molecular pathways involved are critical for immune function. The primary pathway is the JAK-STAT signaling cascade:

1. Cytokine binding to its receptor activates JAK kinases.

2. JAKs phosphorylate STAT3, leading to its dimerization and nuclear translocation.

3. In the nucleus, STAT3 regulates transcription of genes involved in Th17 differentiation, such as RORC and IL17A.

ZNF341 is a transcription factor that binds to the STAT3 promoter, enhancing its expression. In IMD43, loss-of-function mutations in ZNF341 lead to reduced STAT3 levels, impairing Th17 cell development and function.

Data from ClinVar and literature.

The primary deregulated network is the JAK-STAT3 pathway. Key nodes include:

• • JAK1/JAK2: upstream kinases.
• • STAT3: central transcription factor.
• • ZNF341: positive regulator of STAT3 expression.
• • RORC: transcription factor downstream of STAT3, essential for Th17 differentiation.
• • IL17A: effector cytokine produced by Th17 cells.

Additionally, the pathway cross-talks with the PI3K/AKT and MAPK pathways, which may modulate STAT3 activity. In IMD43, reduced STAT3 leads to decreased RORC and IL17A, resulting in impaired mucosal immunity.

Organoids derived from patient-derived induced pluripotent stem cells (iPSCs) can recapitulate the immune phenotype and are useful for studying the disease in a 3D context.

• • ZNF341 knockout mice: These mice exhibit reduced STAT3 expression and impaired Th17 responses, mimicking the human phenotype.
• • Patient-derived xenografts (PDX) are not commonly used for IMD43 due to the immune nature of the disease, but humanized mouse models can be engrafted with patient immune cells.
• • Genetically engineered mouse models (GEMM) with conditional ZNF341 knockout in T cells are useful for studying cell-type-specific effects.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with specific ZNF341 mutations. For example:

• • ZNF341 knockout cell lines: These lines have a complete loss of ZNF341 function, mimicking the most severe forms of IMD43.
• • ZNF341 point mutation knock-in lines: These lines carry specific patient-derived mutations, allowing for genotype-phenotype correlation.

These models are commercially available from various sources and are sequence-verified to ensure accuracy. They are essential for studying the molecular consequences of ZNF341 mutations and for screening potential therapeutic compounds.

Gene-edited cell lines are used to validate the function of ZNF341 and its downstream targets. For example, ZNF341 knockout lines can be used to assess the impact on STAT3 expression and Th17 differentiation. Additionally, CRISPR screens can identify modifiers of the phenotype, providing insights into potential therapeutic targets.

Isogenic pairs (wild-type vs. ZNF341 knockout) are valuable for drug screening. Compounds that restore STAT3 expression or Th17 function can be identified. Furthermore, gene-edited lines can be used to study resistance mechanisms to immunomodulatory drugs, such as JAK inhibitors, which are often used in autoimmune conditions.

CRISPR synthetic lethality screens can identify genes that are essential in ZNF341-deficient cells but not in wild-type cells. These genes could serve as biomarkers or therapeutic targets. Additionally, gene-edited lines can be used to identify secreted proteins that are altered in IMD43, potentially serving as diagnostic biomarkers.